← Back to Search

Phosphodiesterase Type 5 Inhibitor

Sildenafil for Urinary Incontinence

Phase 1

Waitlist Available

Led By Kathleen L Vincent, MD

Research Sponsored by The University of Texas Medical Branch, Galveston

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Postmenopausal females, 50-80 years of age, at the time of consent

Have stress or mixed urinary incontinence, with at least 3 episodes/week

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 weeks

Awards & highlights

Study Summary

This trial is testing whether sildenafil can improve urinary incontinence by improving blood flow and muscle mass in the pelvic floor.

Who is the study for?

This trial is for postmenopausal women aged 50-80 with stress or mixed urinary incontinence, experiencing at least three episodes a week. Participants should be able to follow the study procedures and provide consent. Excluded are those with significant health issues like heart or liver disease, active cancer, untreated endocrine diseases, high BMI (>40), certain infections (HIV/Hepatitis), or on conflicting medications.Check my eligibility

What is being tested?

The trial is testing Sildenafil's effectiveness against urinary incontinence by improving pelvic floor muscle function. Women will either receive Sildenafil or a placebo to see if there's an improvement in their symptoms compared to those not receiving the drug.See study design

What are the potential side effects?

Sildenafil may cause side effects such as headaches, flushing, indigestion, nasal congestion, dizziness, and visual disturbances. It can also potentially affect blood pressure and interact with other medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a woman aged 50-80 and have gone through menopause.

Select...

I experience urinary leaks due to stress or mixed reasons at least 3 times a week.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Urinary Incontinence as measured by Pad Test

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: SildenafilActive Control1 Intervention

Double Blind Sildenafil, 20mg x 3 times a day, 10 weeks.

Group II: PlaceboPlacebo Group1 Intervention

Double Blind Placebo 3 times a day for 10 weeks.

0 / 2Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

The University of Texas Medical Branch, GalvestonLead Sponsor

241 Previous Clinical Trials

56,574 Total Patients Enrolled

2 Trials studying Urinary Incontinence

72 Patients Enrolled for Urinary Incontinence

Kathleen L Vincent, MDPrincipal InvestigatorUniversity of Texas

2 Previous Clinical Trials

25 Total Patients Enrolled

Media Library

Sildenafil (Phosphodiesterase Type 5 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02983461 — Phase 1

Urinary Incontinence Research Study Groups: Sildenafil, Placebo

Urinary Incontinence Clinical Trial 2023: Sildenafil Highlights & Side Effects. Trial Name: NCT02983461 — Phase 1

Sildenafil (Phosphodiesterase Type 5 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02983461 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA endorsed Sildenafil as a viable treatment option?

"Limited clinical data has been collected thus far to support Sildenafil's safety and efficacy, so it received a score of 1."

Answered by AI

Is it possible for me to partake in this medical experiment?

"To participate in this medical trial, prospective participants must be aged between 50 and 80 years old while also presenting symptoms of urinary incontinence. Furthermore, 24 candidates need to be recruited for the study."

Answered by AI

What malady is Sildenafil primarily deployed to alleviate?

"Sildenafil has been proven effective for the management of premature ejaculation, NYHA functional class II-III pulmonary arterial hypertension, and general cases of PAH."

Answered by AI

How many individuals have committed to the research trial?

"This medical trial is no longer enrolling new patients as it was initially posted on March 10th, 2017 and last modified on May 26th of this year. However, there are 146 available clinical trials for urinary incontinence and 23 studies recruiting candidates to test Sildenafil treatments."

Answered by AI

Is the eligibility criteria for this study limited to those over 18 years of age?

"This medical trial is soliciting candidates aged 50 to 80 years old."

Answered by AI

Are there vacancies still available within this clinical trial for participants?

"Results from clinicaltrials.gov display that this medical study, which was first published on March 10th 2017 and last modified May 26 2022 is no longer looking for volunteers; however, there are 169 other trials actively recruiting patients presently."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Use of Sildenafil for Treatment of Urinary Incontinence

2017. "Use of Sildenafil for Treatment of Urinary Incontinence". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02983461.

All > Urinary Incontinence > Viagra